ESMO Breast 2026: Optimizing Immunotherapy in Early TNBC

Key lessons and remaining challenges in the use of immunotherapy for early triple-negative breast cancer were presented by Giampaolo Bianchini, MD, Head of Breast Oncology, Department of Medical Oncology, IRCCS San Raffaele Hospital, and Associate Professor at Vita-Salute San Raffaele University, Milan, Italy, at the ESMO Breast 2026 Congress. In this MEDtalk, he reviews long-term data supporting pembrolizumab-based perioperative treatment, discusses ongoing efforts to optimize treatment strategies, and explores future directions including antibody-drug conjugates, chemotherapy de-escalation, and biomarker-driven patient selection.